Frederic Bibollet-Ruche,Ronnie M. Russell,Wenge Ding,Weimin Liu,Yingying Li,Kshitij Wagh,Daniel Wrapp,Rumi Habib,Ashwin N. Skelly,Ryan S. Roark,Scott Sherrill-Mix,Shuyi Wang,Juliette Rando,Emily Lindemuth,Kendra Cruickshank,Younghoon Park,Rachel Baum,John W. Carey,Andrew Jesse Connell,Hui Li,Elena E. Giorgi,Ge S. Song,Shilei Ding,Andrés Finzi,Amanda Newman,Giovanna E. Hernandez,Emily Machiele,Derek W. Cain,Katayoun Mansouri,Mark G. Lewis,David C. Montefiori,Kevin J. Wiehe,S. Munir Alam,I-Ting Teng,Peter D. Kwong,Raiees Andrabi,Laurent Verkoczy,Dennis R. Burton,Bette T. Korber,Kevin O. Saunders,Barton F. Haynes,Robert J. Edwards,George M. Shaw,Beatrice H. Hahn

Abstract:An effective HIV-1 vaccination strategy will need to stimulate rare precursor B cells of multiple bNAb lineages and affinity mature them along desired pathways. Here, we searched for V2-apex germ line-targeting Envs among a large set of diverse primate lentiviruses and identified minimally modified versions of one chimpanzee SIV Env that bound several human V2-apex bNAb precursors and stimulated one of these in a V2-apex bNAb precursor-expressing knock-in mouse.

A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies